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ORIGINAL ARTICLE
Tetraspanin Tspan9 regulates platelet collagen receptor GPVI lateral
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Martina Morowski4, Rebecca L. Gavin1, Jing Yang1, Pierre-Emmanuel Milhiet5, Fedor Berditchevski6,
Bernhard Nieswandt4, Natalie S. Poulter 7, Steve P. Watson 7, & Michael G. Tomlinson 1
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Abstract
The tetraspanins are a superfamily of four-transmembrane proteins, which regulate the traffick-
ing, lateral diffusion and clustering of the transmembrane proteins with which they interact.
We have previously shown that tetraspanin Tspan9 is expressed on platelets. Here we have
characterised gene-trap mice lacking Tspan9. The mice were viable with normal platelet
numbers and size. Tspan9-deficient platelets were specifically defective in aggregation and
secretion induced by the platelet collagen receptor GPVI, despite normal surface GPVI expres-
sion levels. A GPVI activation defect was suggested by partially impaired GPVI-induced protein
tyrosine phosphorylation. In mechanistic experiments, Tspan9 and GPVI co-immunoprecipi-
tated and co-localised, but super-resolution imaging revealed no defects in collagen-induced
GPVI clustering on Tspan9-deficient platelets. However, single particle tracking using total
internal reflection fluorescence microscopy showed that GPVI lateral diffusion was reduced
by approximately 50% in the absence of Tspan9. Therefore, Tspan9 plays a fine-tuning role in
platelet activation by regulating GPVI membrane dynamics.
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Introduction
Platelets are small, anucleate cells that are essential for haemos-
tasis by aggregating to form a thrombus at sites of vascular
damage. However, platelets also cause thrombosis by aggregating
to block blood flow in diseased arteries following the rupture of
collagen-rich atherosclerotic plaques, which can lead to heart
attack and stroke. Platelet GPVI is established as the major
platelet-activating collagen receptor [1–4], but also binds laminin
[5] and fibrin [6, 7]. GPVI has only a minor role in haemostasis,
but is important in arterial thrombosis, ischaemic stroke and
maintaining vascular integrity during inflammation [8, 9]. The
GPVI signalling pathway is well characterised and is initiated by
phosphorylation of immunoreceptor tyrosine-based activation
motifs (ITAMs) in the FcRγ chain dimer that is associated with
GPVI [1, 4]. This is mediated by Src family tyrosine kinases and
results in the recruitment of the tyrosine kinase Syk to the ITAMs.
This is followed by downstream phosphorylation and assembly of
a signalosome nucleated by the adapter protein LAT, phospholi-
pase Cγ2 (PLCγ2) activation, Ca2+ mobilisation, platelet shape
change, granule secretion, integrin activation and platelet spread-
ing and aggregation [1, 4]. GPVI recognises collagen as a dimer,
and a proportion of GPVI exists as a dimer on resting platelets,
with dimer levels increasing upon platelet activation [10, 11].
GPVI has been reported to be lipid raft-associated [12–14] and
more recently to be a component of a distinct type of microdo-
main formed by tetraspanin transmembrane proteins [15].
However, it is currently unknown how GPVI lateral mobility in
the plasma membrane and compartmentalisation into membrane
microdomains regulates its activation.
The tetraspanins are a superfamily of 33 four-transmembrane
proteins in humans which interact with specific “partner proteins”
and regulate their biosynthesis, intracellular trafficking, lateral
diffusion in the plasma membrane and clustering [16, 17].
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Tetraspanins can self-associate and appear to form nanoclusters
spanning approximately 100 nm and containing approximately ten
molecules of a single type of tetraspanin [18]. To date five
tetraspanins have been investigated on platelets using knockout
mice: CD9, CD63, CD82, CD151 and Tspan32. Mice deficient in
either CD151 or Tspan32 have similar phenotypes, namely a
partial defect in platelet aggregation and haemostasis that is
proposed to be due to impaired outside-in signalling of the
major platelet integrin αIIbβ3 [19–21]. Conversely, deficiency in
either CD9 or CD63 causes a mildly hyperactive platelet pheno-
type without affecting haemostasis [22, 23]. CD82 deficiency
results in more substantially hyperactive platelets, with enhanced
haemostasis in vivo and enhanced clot retraction in vitro [24].
Platelets express additional tetraspanins, but their functions on
platelets are yet to be characterised [25–27].
We previously identified Tspan9 as a tetraspanin that is
expressed on platelets, but not several other cell types tested
[15]. In the current study, we report the first characterisation of
a Tspan9-deficient mouse. The mice were viable and had normal
platelet count, size and levels of major platelet antigens. However,
we demonstrate that Tspan9 contributes to GPVI-induced platelet
activation and regulates its membrane dynamics.
Methods
Mice
Tspan9 knockout mice were generated from C57BL/6 mouse
embryonic stem cells containing a gene-trap vector (clone
IST11668F5) at the Texas Institute for Genomic Medicine,
Houston, Texas, USA. Heterozygous breeding pairs were used to
generate Tspan9 knockout mice with litter-matched controls, and
mice were aged at least 8 weeks before use in experiments. GPVI-
deficient mice [28] were kindly provided by Prof Jerry Ware
(University of Arkansas for Medical Sciences, Little Rock,
Arkansas, USA). Mouse experiments at the Biomedical Services
Unit, University of Birmingham, UK, were performed in accor-
dance with the Animals (Scientific Procedures) Act 1986. Mouse
experiments in Würzburg, Germany, were approved by the District
Government of Lower Franconia (Bezirksregierung Unterfranken).
Antibodies and reagents
The rabbit anti-Tspan9 polyclonal antibody was as previously
described [15], anti-α-tubulin monoclonal DM1A was from
Sigma, anti-phosphotyrosine monoclonal 4G10 was from
Millipore, anti-LAT phospho-specific antibodies were from
Abcam, anti-human GPVI monoclonal HY101 for biochemical
experiments was kindly provided by Dr Peter Smethurst (NHS
Blood and Transplant, Cambridge, UK), anti-human GPVI mono-
clonal 1G5 for microscopy was kindly provided by Dr Elizabeth
Gardiner (The John Curtin School of Medical Research,
Canberra, Australia) [29] and mouse IgG1 isotype control mono-
clonal MOPC-21 was from Sigma. Fluorescently labelled mono-
clonal antibodies used for flow cytometry and single particle
tracking were from Emfret, apart from anti-mouse integrin α6
(AbD Serotec), anti-mouse CLEC-2 17D9 [30] and anti-
ADAM10 and anti-CD9 (R&D Systems). Atto 647N and 565
fluorescent dyes were from Sigma, and 3,3′-dihexyloxacarbocya-
nine iodide (DiOC6) membrane dye was from Molecular Probes.
Platelet agonists were cross-linked collagen-related peptide (CRP)
from Prof Richard Farndale (Cambridge University, UK), Horm
collagen from Takeda, ADP from Sigma, protease-activated
receptor (PAR)-4 peptide (AYPGKF) from Alta Bioscience and
arachidonic acid from Cambridge Bioscience.
Flow cytometry
Mouse platelet flow cytometry was performed on whole blood,
and data were collected using CellQuest and a FACSCalibur (BD
Biosciences).
Immunohistochemistry
Paraffin sections of 5 μm from formalin-fixed blocks, of wild-
type and Tspan9-deficient mouse tissues, were processed for
immunohistochemistry as described previously [31].
Platelet preparation
Human and mouse platelet-rich plasma and washed platelets were
isolated from whole blood as previously described [32, 33].
Consent for human blood was obtained from each donor, and
platelet preparation was carried out with ethical approval.
Mouse whole blood counts were assessed using an ABX Pentra
60 haematology analyser (Block Scientific).
Platelet biochemistry
For platelet stimulation and subsequent detection of protein tyrosine
phosphorylation, platelets were pre-treated with 10 µM lotrafiban, 2
units/mL apyrase and 10 µM indomethacin, and then stimulated and
subjected to lysis and western blotting as described [33]. For co-
immunoprecipitation experiments, 1 × 109 washed human platelets
were lysed in 1% Brij97 lysis buffer [15] and pre-cleared with 20 µL
protein G sepharose beads for 60 minutes at 4°C. Pre-cleared lysates
were immunoprecipitated with isotype control (MOPC-21) or anti-
human GPVI (HY101) antibodies, coupled to protein G sepharose,
by rotating for 90minutes at 4°C. Samples werewashed in 1%Brij97
lysis buffer, separated by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) and western blotted for Tspan9 and
GPVI.Western blots were probed with IRDye fluorescent secondary
antibodies (LI-COR Biosciences) and imaged and quantified using
the Odyssey Infrared Imaging System (LI-COR Biosciences), or
were probed with horseradish peroxidase-conjugated secondary
antibodies and developed with enhanced chemiluminescence
(ECL) and film.
In vitro platelet function assays
Lumi-aggregometry was conducted as previously described [34].
For the platelet flow adhesion assay, flow cells in a 24-well plate
format (Fluxion) were coated with 30 µg/mL collagen for one
hour and blocked with 5 mg/mL of denatured, filtered fatty acid-
free bovine serum albumin at 4 °C overnight. Blood was incu-
bated with 0.2 µM DiOC6 membrane dye at 37°C for 10 minutes
and then perfused through the flow cell at a shear rate of 1000 s−1
at 37°C using the BioFlux 200 Microfluidic Flow System
(Fluxion). Images were continuously taken by fluorescence
microscopy using a TE2000 Nikon microscopy system, with a
40× plan APO/1.4 NA oil-immersion DIC objective.
In vivo platelet function assays
Bleeding time was assessed in the mice using a previously
described tail bleeding assay [34]. Intravital assessment of in vivo
thrombus formation, after topical application of FeCl3 to mesen-
teric or carotid arteries, was done as previously described [35].
Platelet spreading and staining for microscopy
Mouse or human platelet-rich plasma was diluted to 2 × 107
platelets/mL in modified Tyrode’s buffer [33]. Mouse platelets
were pre-incubated with 5 μg/mL of rat anti-mouse GPVI clone
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JAQ3 [36] for 10 minutes at 37°C and then allowed to spread on
glass-bottom dishes coated with 10 µg/mL collagen for 45 min-
utes at 37°C. Human platelets were pre-incubated with 5 μg/mL
of mouse anti-human GPVI clone 1G5 and then similarly
spread on collagen. Adhered platelets were washed once with
phosphate-buffered saline (PBS) and fixed with 10% formalin
solution for 10 minutes. Fixed platelets were rinsed with PBS
three times and permeabilised with 0.1% Triton X-100 in PBS for
5 minutes. Fixed platelets were then washed three times with
PBS. Mouse platelets were stained with an Alexa 647-conjugated
goat anti-rat antibody and Alexa 488-conjugated phalloidin in
blocking buffer (1% bovine serum albumin and 2% goat serum
in PBS). Human platelets were co-stained with 5 μg/mL mouse
anti-human GPVI clone 1G5 and 2 μg/mL rabbit anti-Tspan9,
washed three times with PBS and stained with Alexa 647-con-
jugated goat anti-mouse antibody and Alexa 488-conjugated goat
anti-rabbit antibody in blocking buffer.
Confocal reflection and fluorescence microscopy
Fixed and stained platelet samples were imaged by confocal
microscopy using the 488 nm Argon laser line and 633 nm laser
line (He/Ne laser) of a Leica SP2 inverted confocal with the 63 ×
1.4 NA oil objective. Reflected light was collected from the 488
nm excitation wavelength. Confocal z-stacks of platelets were
acquired using the Leica TSC SP2 software with images taken
at 0.25 µm intervals. Four fields of view were taken per treatment,
per experiment. To determine the extent of co-localisation
between Tspan9 and GPVI on human platelets spread on collagen,
the two-colour image was first de-noised in ImageJ using an
image restoration algorithm based on the assumption of Poisson
noise [37]. Background subtraction was performed in MATLAB
using a rolling balling approach in which the radius of the ball
was selected to be greater than image features (1 µm). A Costes’
approach was used to automate threshold selection for signal
isolation and to determine P values for each z-stack [38], where
the null hypothesis was randomly distributed signal within the
region of interest. This region of interest was defined by manual
segmentation of the platelets and collagen fibres using the inter-
ference reflectance channel. The Manders’ coefficients (M1 and
M2) were used as the co-localisation measure [39].
Direct stochastic optical reconstruction microscopy imaging
and cluster analysis
Fixed and stained mouse platelet samples were imaged in direct
stochastic optical reconstruction microscopy (dSTORM) mode
using a 100 × 1.49 NA total internal reflection fluorescence
Table I. Tspan9-deficient mice have platelets of normal count and size, and normal numbers of other blood cell parameters. Whole blood from wild-
type (WT) and Tspan9-deficient (KO) mice was analysed using an ABX Pentra 60 haematology analyser from Block Scientific. Data are presented as
means and standard deviations from between 18 and 20 litter-matched pairs of mice. No significant differences were revealed using unpaired t-tests.
Blood parameter WT KO
Platelet count (103/mm3) 892 ± 159 924 ± 281
Platelet volume (µm3) 5.36 ± 0.25 5.35 ± 0.27
Plateletcrit (%) 0.29 ± 0.07 0.29 ± 0.07
White blood cell count (103/mm3) 8.24 ± 3.94 8.30 ± 4.04
Red blood cell count (106/mm3) 10.3 ± 1.12 10.1 ± 0.73
Haemoglobin concentration (g/dL) 9.15 ± 0.61 9.34 ± 0.64
Haematocrit (%) 29.4 ± 2.4 30.7 ± 5.1
Red blood cell distribution width (%) 12.8 ± 0.78 12.8 ± 0.54
Mean corpuscular volume (µm3) 47.9 ± 1.3 48.3 ± 1.3
Mean corpuscular haemoglobin (pg) 15.1 ± 0.51 16.9 ± 7.9
White cell percentages:
- Lymphocytes 86.2 ± 6.9 85.1 ± 7.4
- Monocytes 4.18 ± 1.97 4.90 ± 2.48
- Neutrophils 7.69 ± 4.24 8.29 ± 4.35
- Eosinophils 1.17 ± 1.41 0.97 ± 1.37
- Basophils 0.76 ± 0.90 0.65 ± 1.02
Figure 1. Tspan9 is not detectable in platelets
and lung from Tspan9-deficient mice. Platelets
from wild-type (WT), heterozygote (Het) and
Tspan9-deficient (KO) mice were lysed in 1%
Triton X-100 lysis buffer, the proteins separated
by SDS-PAGE and western blotted for Tspan9
(upper panel) and α-tubulin to confirm equal
protein loading (lower panel), using the Odyssey
Infrared Imaging System. Mouse lung samples
were homogenised in 1% Triton X-100 lysis
buffer and western blotted as described for the
platelets.
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(TIRF) objective lens on a Nikon N-STORM system consisting of
a Ti-E stand with Perfect Focus, Agilent MLC400 high-power
laser bed (647 nm laser line) and Andor iXon Ultra 897 EMCCD
camera. Samples were imaged in a PBS buffer containing cata-
lase (1 μg/mL), mercaptoethylamine-HCl (100 mM), glucose
(40% v/v) and glucose oxidase (50 μg/mL) to induce fluorophore
blinking. Twenty thousand frames were captured using Nikon
NIS Elements AR v4.5, with an exposure time of 9.2 ms, gain
300 and conversion gain 3, and then reconstructed using STORM
analysis module 3.2. Detected molecules (fluorescent blinks) of a
photon count of less than 500 were filtered out of the final
reconstruction. Samples were drift corrected and rendered using
Gaussian rendering. Cluster analysis was performed on the
dSTORM data in MATLAB, using a custom-made algorithm
based on Ripley’s K-function [40] with modifications as
described [41]. For the analysis, 2 × 2 µm regions of interest
were analysed for clustering with the spatial scale r = 50 nm used
to generate the pseudo-coloured cluster heat map, where red
indicates high degrees of clustering. Binary maps were generated
from these cluster heat maps by threshold application. Areas of
the heat map that were above the upper threshold of L(50) = 100
were defined as clusters. Information on the clusters was
Figure 2. Tspan9 expression in mouse tissues is
restricted to megakaryocytes and a limited range
of other cell types including some endothelial
and epithelial cells. Immunohistochemistry was
performed on sections from wild-type (WT) and
Tspan9-deficient tissues as a negative control
(KO). The scale bar is 100 µm.
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extracted from the binary map, including the number of mole-
cules and the size of clusters. A total of 179 regions of interest
from wild-type and 177 regions of interest from Tspan9-deficient
mice, from four independent experiments, were analysed for
GPVI clustering on collagen.
GPVI and CD9 single particle tracking
Fab fragments from anti-GPVI monoclonal antibody JAQ1 [42]
and anti-CD9 monoclonal antibody Nyn.H3 were coupled to Atto
647N or 565 as described previously [43]; 500 µL of washed
mouse platelets at 2 × 107/mL was allowed to spread directly on
cleaned glass coverslips for 35 minutes at 37°C. Non-adhered
platelets were removed by gentle washing with modified
Tyrode’s buffer [33]. The relevant antibodies and the membrane
dye DiOC6 were incubated for 10 minutes at 37°C with the
spread platelets at a final concentration of 10 ng/mL for JAQ1,
5 ng/mL for CD9, 50 ng/mL for IgG controls and 0.2 µM for
DiOC6. Unbound antibody was removed by gentle washing with
Tyrode’s buffer. Platelets were imaged at 37°C using an Olympus
IX81-ZDC dual TIRF microscope with a Hamamatsu EM-CCD
digital camera using an Olympus 150× UAPO N 1.45 NA immer-
sion oil TIRF objective with Violet Diode 400–405 nm, ArgonIon
457–514 nm and Green Diode 561 nm lasers. Five hundred
images were captured every 130 ms to generate a video. Laser
power was kept to a minimum, to avoid untimely bleaching of the
fluorophores, and camera gain was set to maximum. At least ten
different fields of view were imaged for each condition. Single
particle tracking videos were analysed using PaTrack software
and the previously described parameters for trajectory inclusion
criteria and determination of motional modes (Brownian, con-
fined or directed) [44].
Results
Generation of Tspan9-deficient mice
We previously generated Tspan9 antibodies to demonstrate
expression of this tetraspanin by platelets and in certain tissues
such as lung [15]. In order to investigate the function of Tspan9, a
Tspan9-deficient mouse was generated using gene-trap embryonic
stem cells on the C57BL/6 background. The mice were viable,
normal in weight, born at expected Mendelian frequencies when
bred as heterozygotes and fertile as homozygotes (data not
shown). The platelets were normal in size and count, as were
other blood cell parameters (Table I). Loss of Tspan9 protein
expression was confirmed by western blotting of lysates from
platelets and lung, which showed an approximately 50% reduction
of protein in heterozygotes and complete loss in homozygote
knockouts (Figure 1).
Tspan9 expression in mouse tissues
To further investigate the Tspan9 expression profile, expression in
various mouse tissues was assessed by immunohistochemistry,
using tissues from Tspan9-deficient mice as a negative control.
Analyses of bone marrow revealed Tspan9 expression in rela-
tively large cells characteristic of megakaryocytes (Figure 2),
which was consistent with our previous identification of Tspan9
expression in platelets and their megakaryocyte progenitors [15].
Blood vessels also appeared positive for Tspan9 (Figure 2).
Tspan9 was prominent in lung, again in agreement with our
previous western blotting data [15], and appeared to be localised
to the endothelial cells of interalveolar walls and the basal aspect
of bronchial epithelial cells (Figure 2). Tspan9 was also expressed
in the sinusoidal endothelial cells of the liver, small vessels and
capillaries of the heart, the red pulp of the spleen, which is rich in
sinusoidal venous endothelial cells, and cells of the glandular
layer of the skin (Figure 2). In each case, no Tspan9 expression
was detected in Tspan9-deficient tissues (Figure 2). These data
are consistent with Tspan9 expression in the platelet/megakaryo-
cyte lineage, in addition to a limited range of other cell types
including some endothelial and epithelial cells.
Tspan9-deficient platelets have a mild but specific GPVI
activation defect
To determine whether platelets were defective in levels of major
surface glycoproteins in the absence of Tspan9, they were first
analysed by flow cytometry. Expression of the following was not
affected by the lack of Tspan9: the platelet-activating receptors
GPVI and CLEC-2, the tetraspanin CD9, the metalloproteinase
ADAM10, the von Willebrand factor receptor GPIb and the
integrins αIIbβ3, α2β1 and α6β1 (Table II).
To assess platelet function, aggregation assays were performed
using platelet-rich plasma. Tspan9-deficient platelets were defec-
tive in aggregation induced by the GPVI-specific agonist cross-
linked collagen-related peptide (CRP) at an intermediate concen-
tration of 3 µg/ml (Figure 3A). This was a mild defect which was
overcome at 10 µg/ml of CRP (Figure 3B). No defect was evident
with 3 µg/ml of the physiological GPVI agonist collagen
(Figure 3C), which also binds to integrin α2β1. The aggregation
defect was specific to GPVI because no defect was observed in
response to arachidonic acid, PAR4 peptide or ADP (Figure 3D–
F), which activate platelets via distinct G protein-coupled recep-
tors (GPCRs). Similarly, no defect was observed at lower con-
centrations of collagen or the GPCR agonists (data not shown).
Consistent with these aggregation data, a lack of dense granule
secretion was evident when platelet-rich plasma was stimulated
with 3 µg/ml of CRP (Figure 3G), but not in response to 10 µg/ml
CRP (Figure 3H), collagen (Figure 3I) and arachidonic acid
(Figure 3J). A significant defect in PAR4 peptide-induced secre-
tion was observed, but this was only a 20% decrease (Figure 3K);
since there was no PAR4 aggregation defect (Figure 3E), a role
for Tspan9 in PAR4-induced platelet activation appears unlikely.
To test whether a Tspan9 collagen aggregation phenotype could
be revealed at a 50% reduced surface expression level of GPVI,
which could make a role for Tspan9 in regulating GPVI more
critical, Tspan9-deficient mice were crossed with GPVI-deficient
mice [28]. This allowed the effect of Tspan9 deficiency to be
investigated on a GPVI-heterozygous background. However, no
significant defect in collagen-induced aggregation was detected in
the absence of Tspan9, even at the relatively low collagen con-
centration of 1 µg/ml (Figure 4A). Approximately 50% reduced
Table II. Tspan9-deficient platelets express normal levels of the major
platelet surface glycoproteins. Whole blood from wild-type (WT) and
Tspan9-deficient (KO) mice were stained with fluorescent-conjugated
antibodies, and platelet-specific staining was determined following gating
by size. Isotype negative control staining was subtracted, and geometric
mean fluorescence intensities with standard deviations are presented from
between 3 and 8 pairs of litter-matched mice. No significant differences
were determined using unpaired t-tests.
Surface protein WT KO
α2 integrin 18.0 ± 0.9 16.2 ± 0.6
αIIb integrin 1113 ± 108 1153 ± 73
α6 integrin 158 ± 4.1 161 ± 0.9
ADAM10 33.7 ± 1.7 38.2 ± 2.4
CD9 905 ± 65 883 ± 61
GPIb 504 ± 11 489 ± 25
GPVI 125 ± 4.5 120 ± 3.3
CLEC-2 109 ± 26 110 ± 26
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surface levels of GPVI in the heterozygous genotypes were con-
firmed by flow cytometry (Figure 4B).
To test whether Tspan9-deficient platelets were defective in
GPVI-induced signalling, tyrosine phosphorylation was measured
by western blotting of whole cell lysates following stimulation
with CRP. A mild reduction in intensity of some phosphoproteins
was apparent in the absence of Tspan9 over the 60 second time
course (Figure 5A), including the phosphoproteins of 100 and 72
kD (Figure 5B and C). Another affected phosphoprotein was the
transmembrane adapter protein LAT, which exhibited a signifi-
cant 40%–50% reduction in phosphorylation on tyrosines at posi-
tions 200 and 226 (Figure 5D and E).
Together these data demonstrate that Tspan9-deficient plate-
lets have mild defects in GPVI-induced tyrosine phosphorylation
and platelet aggregation and secretion, despite normal surface
expression of GPVI.
Tspan9 is not essential for haemostasis or thrombosis
A series of experiments were designed to test whether Tspan9-
deficient platelets had any defect in aggregate formation on col-
lagen under in vitro flow conditions, and whether the Tspan9-
deficient mice had any haemostasis or thrombosis defects. No
defect in aggregate formation on collagen under in vitro flow
conditions was observed in the absence of Tspan9 (Figure 6A
and B), and there was no haemostasis phenotype using the tail
bleed assay (Figure 6C). Furthermore, in a ferric chloride injury
model of in vivo thrombosis, the absence of Tspan9 had no effect
Figure 3. Tspan9-deficient platelets have a mild
but specific defect in GPVI-induced platelet
aggregation and secretion. Wild-type (WT) and
Tspan9-deficient (KO) platelets in platelet-rich
plasma were activated with the GPVI-specific
agonist cross-linked collagen-related peptide
(CRP) at [A, G] 3 µg/mL and [B, H] 10 µg/mL,
[C, I] collagen, [D, J] arachidonic acid, [E, K]
PAR4 peptide and [F] ADP. [A–F] Aggregation
was measured by light transmission with stir-
ring. [i] Representative traces and [ii] quanti-
tated percentage aggregation each minute are
shown. A two-way ANOVA was performed on
arcsine-transformed data followed by a
Bonferroni post-test (*** denotes P < 0.001).
[G–K] ATP secretion was measured by lumi-
aggregometery. Significance was determined by
an unpaired t-test (* denotes P < 0.05 and ***
denotes P < 0.001). Error bars represent the
standard error of the mean from between three
and nine pairs of litter-matched mice.
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on vessel occlusion times in large (carotid) or intermediately sized
(mesenteric) arteries (Figure 6D and E).
Tspan9 associates with GPVI
To elucidate the mechanism by which the loss of Tspan9 affects
GPVI activation, we first investigated whether GPVI interacts with
Tspan9. Human platelets were lysed in 1% Brij97 and then subjected
to GPVI immunoprecipitation and Tspan9 western blotting. This
demonstrated that Tspan9 was co-immunoprecipitated by GPVI
(Figure 7A). However, the interaction was not observed in more
stringent 1% digitonin lysis buffer (data not shown), suggesting a
weak or indirect interaction. To test whether GPVI and Tspan9 co-
localise, co-immunofluorescence confocal microscopy was carried
out on human platelets spread on collagen. GPVI co-localised with
collagen fibres and partially with Tspan9 (Figure 7B). Quantitation
of these data using the Manders’ coefficients revealed that approxi-
mately 60% of Tspan9 staining overlapped with GPVI, and vice
versa (Figure 7C), which is consistent with the similar copy numbers
of Tspan9 and GPVI on platelets [15]. These two sets of experiments
suggest that a proportion of Tspan9 associates with GPVI.
Tspan9 does not affect GPVI clustering on platelets spread
on collagen
It is well established that certain tetraspanins can promote the
clustering of their partner proteins [16]. To determine whether
GPVI clustering on collagen was affected in the absence of
Tspan9, GPVI was imaged by confocal microscopy using Fab
fragments of GPVI monoclonal antibody JAQ3, which does not
interfere with collagen binding [36], on human platelets spread for
45 minutes on collagen. GPVI co-localised with collagen fibres
on both wild-type and Tspan9-deficient platelets, but no differ-
ences were apparent at this resolution (Figure 8A and B). To
investigate GPVI clustering at the super-resolution level, GPVI
was imaged using dSTORM (Figure 8C and D). Cluster analysis
(Figure 8E and F) showed no difference in GPVI density
(Figure 8G) or number of GPVI clusters (Figure 8H), suggesting
that Tspan9 does not affect GPVI clustering on collagen.
However, this assay was performed on fully spread platelets,
which may not detect delays in GPVI clustering.
Tspan9 promotes GPVI lateral diffusion
Tetraspanins are emerging as regulators of the lateral diffusion of
the transmembrane proteins with which they interact [45–48]. To
determine whether Tspan9 regulates GPVI lateral mobility, single
particle tracking was developed for the first time in platelets.
Mouse platelets were allowed to spread on glass coverslips and
then incubated with single Atto 647N-labelled anti-GPVI Fab
fragments. The plane of the plasma membrane was then imaged
using TIRF microscopy every 130 ms for a total of 500 times. The
trajectory type and apparent diffusion coefficient of individual
labelled particles were then determined using PaTrack software
[43]. In wild-type platelets, three different motion types were
detected for GPVI trajectories: purely Brownian motion (40% of
total trajectories), confined or restricted diffusion (42%) and
trajectories with both Brownian and confined elements (18%)
(Figure 9A). In Tspan9-deficient platelets, the three motion
types were also displayed by GPVI molecules, but the percentage
of Brownian motion significantly decreased by 30% compared to
wild type, and confined or restricted trajectories significantly
increased by 26% (Figure 9A). This significantly reduced the
median apparent diffusion coefficient of the GPVI population
by 43%, from 0.021 on wild-type to 0.012 µm2/s on Tspan9-
deficient platelets (Figure 9B).
To determine whether the absence of Tspan9 could similarly
affect the diffusion of other membrane proteins, platelets were co-
labelled with single Atto 565-labelled CD9 Fab. In contrast to
GPVI, there was no significant difference in the relative fre-
quency of confined or restricted CD9 trajectories in wild-type
versus Tspan9-deficient platelets, although there was a small but
significant 4.5% increase in the relative frequency of CD9 parti-
cles that displayed mixed (Brownian and confined) diffusion
(Figure 9C). This change in diffusion behaviour affected the
total population of tracked CD9 particles, causing a small but
significant difference in the median apparent diffusion coefficient
from 0.029 on wild-type to 0.025 µm2/s on Tspan9-deficient
platelets, representing a 14% decrease (Figure 9D).
In summary, the GPVI lateral diffusion and signalling
defects in the absence of Tspan9 suggest that this tetraspanin
maintains a relatively mobile population of GPVI molecules,
with the potential to rapidly cluster and signal upon ligand
engagement.
Figure 4. Tspan9-deficient platelets have normal aggregation responses to collagen. [A] Tspan9 (T9)-deficient mice were crossed with GPVI (G6)-
deficient mice to generate Tspan9-deficient mice on a GPVI heterozygote (Het) or wild-type (WT) background. Platelet-rich plasma from these mice
was activated with 1 µg/mL collagen, and aggregation was measured by light transmission with stirring. Quantitated percentage aggregation data for
each minute are shown; error bars represent standard error of the mean from seven mice per genotype. A two-way ANOVA performed on arcsine-
transformed data revealed no significant differences. [B] Whole blood was analysed by flow cytometry for GPVI, as described in the legend for
Table II. Error bars represent standard deviation from three to four mice per genotype. Significance was determined by a one-way ANOVA followed by
a Tukey’s post-test (* denotes P < 0.05).
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Discussion
This study represents the first characterisation of the Tspan9-
deficient mouse. We have discovered that Tspan9 is necessary
for normal platelet protein tyrosine phosphorylation, aggregation
and secretion following activation through the collagen receptor
GPVI. Moreover, GPVI lateral mobility on the cell surface was
reduced by approximately 50% in the absence of Tspan9. Since
GPVI clustering is important for its activation and signalling [10,
11], a reduction in its lateral diffusion could explain the observed
platelet aggregation and secretion defects. No defects in GPVI
clustering on collagen were observed by super-resolution ima-
ging, but these experiments were done on fully spread platelets
and would not detect a delay in the kinetics of clustering.
Tetraspanins are thought to function by interacting with
specific partner proteins and regulating their trafficking and
membrane dynamics. Definitive tetraspanin/partner pairs
include tetraspanin CD151 with laminin-binding integrins
[17], CD81 with the B-cell co-receptor CD19 [49] and the
TspanC8 subgroup of tetraspanins with a disintegrin and metal-
loproteinase 10 (ADAM10) [26]. Their interactions can be
Figure 5. GPVI signalling is impaired in Tspan9-deficient platelets. [A] Washed platelets from wild-type (WT) and Tspan9-deficient (KO) mice were
activated with 3 μg/mL cross-linked collagen-related peptide (CRP), and samples were taken at 0, 10, 30 and 60 second time points and lysed in 1% Triton
X-100 lysis buffer. Proteins were separated by SDS-PAGE and blotted with the 4G10 anti-phosphotyrosine antibody (upper panel) or phospho-specific
antibodies to LAT phosphotyrosines 226 or 200 or α-tubulin to control for protein loading (lower panels). The blots were visualised using the Odyssey
Infrared Imaging System, and band intensities of the whole cell phosphoproteins of [B] 100 kD (pp100) and [C] 72 kD (pp72), LAT phosphotyrosine [D] at
amino acid position 226 and [E] 200 were quantitated and normalised to tubulin. Significance was determined by a two-way ANOVA followed by a
Bonferroni post-test (* denotes P < 0.05 and ** denotes P < 0.01). Error bars represent the standard error of the mean from three pairs of litter-matched mice.
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detected by co-immunoprecipitation in relatively stringent lysis
conditions (e.g. 1% Triton X-100 or digitonin). Moreover,
defects in partner protein trafficking to the cell surface and/or
membrane dynamics can be observed following tetraspanin
knockdown or knockout, and tetraspanin deficiency typically
phenocopies partner protein deficiency [16]. Tspan9 and GPVI
have similar expression levels in platelets [15], but the data in
the present study are not definitive in showing that GPVI is a
bona fide partner for Tspan9. We found that GPVI and Tspan9
could be co-immunoprecipitated from human platelets, but only
in relatively non-stringent 1% Brij lysis buffer, and the inter-
action was not maintained in 1% digitonin (data not shown). In
addition, only a partial co-localisation was observed by con-
focal microscopy. GPVI surface expression levels were not
affected by the loss of Tspan9, suggesting that it does not
regulate steady-state expression of GPVI on the cell surface,
but GPVI lateral mobility was reduced. Finally, Tspan9 defi-
ciency only weakly phenocopied GPVI deficiency, since the
GPVI-specific platelet activation and aggregation defects were
not detected in response to the physiological agonist collagen,
even at low agonist concentration and in GPVI-heterozygous
platelets in which a Tspan9 function might have been more
critical. Moreover, the aggregation and secretion defects in
response to the GPVI-specific agonist CRP were overcome by
increased CRP concentrations. It is possible that signalling
induced by the collagen-binding integrin α2β1 [50, 51] is
sufficient to overcome the mild GPVI-induced aggregation
defect. In vivo Tspan9-deficient mice had no arterial thrombo-
sis defects in GPVI-dependent models. It is therefore possible
that Tspan9 does not directly interact with GPVI, but modu-
lates the collagen receptor by regulation of another protein that
is important for GPVI membrane dynamics. Alternatively,
Tspan9 could directly engage in relatively low affinity interac-
tions with a subpopulation of GPVI molecules, enhancing their
lateral diffusion by an undefined mechanism.
Two previous single particle tracking studies have reported the
promotion of partner protein lateral diffusion by a tetraspanin.
Firstly, epidermal growth factor receptor lateral diffusion is
reduced by almost 50% following knockdown of tetraspanin
CD82 in the HeLa epithelial cancer cell line [45]. Secondly,
ADAM10 lateral diffusion is almost twofold increased by
Tspan15 expression in the U2OS osteocarcinoma cell line [46].
In contrast, two other single particle tracking studies have shown
that tetraspanins confine their partners. The proportion of con-
fined α6 integrin is decreased by 75% on a mammary cell line
upon CD151 knockdown, consistent with the idea that CD151
clusters the integrin within nanodomains [48]. Furthermore,
CD19 lateral diffusion is increased by 2.5-fold on B cells from
CD81-knockout mice [47]. It is proposed that CD81 confines
CD19 into nanoclusters that can interact with activated B-cell
receptors to promote signalling [47]. The mechanisms by which
tetraspanins exert their effects on partner protein dynamics are
currently unknown.
CD9 lateral diffusion was also reduced in the absence of
Tspan9, but this was a weaker effect than for GPVI. Moreover,
unlike GPVI, no decrease in CD9 Brownian motion and increase
in confined motion types were observed. The lateral diffusion of
CD9 on wild-type platelets (0.029 µm2/s) was substantially lower
than previously reported for CD9 on PC3 and HeLa epithelial
cancer cells (0.23 and 0.24 µm2/s, respectively) [43, 52], and for
the related CD81 on HepG2 liver cancer cells (0.11 µm2/s on non-
polarised and 0.07 µm2/s on polarised cells) [53]. This may be
Figure 6. Tspan9-deficiency does not affect adhesion to collagen under flow, haemostasis or arterial thrombosis. [A] To assess adhesion to collagen
under flow, heparinised whole blood from wild-type (WT) and Tspan9-deficient (KO) mice was incubated with 0.2 µM DiOC6 membrane dye and
perfused over a collagen-coated flow cell (30 µg/mL) using the Fluxion Bioflux system at a shear rate of 1000 s−1. Representative fluorescence images
are shown after 1, 2, 3 and 4 minutes, with flow from left to right. [B] Coverage of the flow cell by aggregates was measured using thresholding in
ImageJ. Quantitation revealed no significant differences following a two-way ANOVA with Bonferroni post-test on arcsine-transformed data. Error
bars represent standard error of the mean from three litter-matched pairs of mice. [C] To assess haemostasis, wild-type (WT) and Tspan9-deficient
(KO) mice were assessed for tail bleeding by excising 2 mm tail tips from anaesthetised mice and measuring the weight of blood lost as a factor of
mouse weight. No significant difference was determined using an unpaired t-test. Error bars represent standard error of the mean from 20 litter-matched
pairs of mice. [D-E] To assess chemical injury-induced thrombosis, platelets were fluorescently labelled with Dylight-488-conjugated anti-GPIX
antibody. Mice were anaesthetised, and the carotid artery [D] or mesentery [E] was exteriorised. FeCl3-induced chemical injury was induced via topical
application to the vessels. Time to complete occlusion of the vessel was measured using fluorescence intravital microscopy. No significant difference
was determined using an unpaired t-test for panels D or E.
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due to the relatively high density of platelet CD9, as the second
most highly expressed surface protein on these cells [15, 25].
Indeed, the relatively high proportion of confined CD9 on plate-
lets is consistent with the capacity for CD9 to form platforms in
which individual CD9 molecules can be transiently confined [43].
In addition to expression in platelets, immunohistochemistry
demonstrated Tspan9 expression in endothelial cells of the lung,
liver, heart and spleen, and some lung epithelial cells. However,
no effects of Tspan9 deficiency were observed in the gross mor-
phology of these organs. Elucidation of tetraspanin function using
knockout mice can be complicated by functional redundancy
between tetraspanins, which share relatively strong protein
sequence identity. For example, CD9 and CD81 share 45%
identity, and double-deficient mice have macrophage dysfunction
leading to a phenotype that resembles chronic obstructive pul-
monary disease; neither single knockout has detectable disease
[54]. Tspan9 has relatively strong sequence identity with Tspan4
(55%) and CD53 (43%), for which knockout mice phenotypes
have yet to be reported. CD53 is restricted to leukocytes [55]
and is absent from platelets [56, 57], so its expression does not
appear to overlap with Tspan9. Tspan4 appears to be more widely
expressed [58] but not by platelets [56, 57]. These expression
profiles could explain how a platelet phenotype has been identi-
fied in the Tspan9-deficient mice. Moreover, co-expression of
Tspan9 and Tspan4 in endothelial and epithelial cells could
explain the lack of a noticeable Tspan9 phenotype in these cells.
Figure 7. Tspan9 associates with GPVI on human platelets. [A] Washed human platelets were lysed in 1% Brij97 lysis buffer and subjected to
immunoprecipitation with isotype control or anti-GPVI antibodies. Immunoprecipitates were analysed by SDS-PAGE and western blotting for Tspan9
(top panel) and GPVI (lower panel) using ECL and film. [B] Human platelets were spread on collagen and imaged by confocal microscopy following
immunostaining for GPVI (top panel) and Tspan9 (middle panel). Interference reflectance was used to determine the position of the platelets and
collagen fibres (lower panel). [C] The Manders’ coefficients (M1 and M2) were calculated from the confocal stacks to quantify the degree of overlap.
All Costes P values for individual stacks were <0.001, indicating significant partial co-localisation in all cases.
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Tspan9 has recently been identified as a novel host factor for
the infection of the U2OS osteocarcinoma cell line with alpha-
viruses [59]. These are small enveloped plus-sense RNA viruses
which can cause arthritis and encephalitis following transmission
by mosquitos. There are presently no treatments or vaccine for
alphaviruses. Tspan9 is localised to the plasma membrane and
early and late endosomes in these cells. It is necessary on early
endosomes for viral membrane fusion with the endosomal mem-
brane, which allows infection by releasing the viral nucleocapsid
into the cytoplasm [60]. The Tspan9-deficient mice may be a
useful model system to assess the importance of Tspan9 in alpha-
virus infection in vivo.
In summary, we have performed the first characterisation of
Tspan9-deficient mice and identified a mild but specific defect
in platelet activation via the collagen receptor GPVI. Single
particle tracking demonstrated altered diffusion characteristics
of GPVI in the absence of Tspan9. We propose that Tspan9
maintains a relatively mobile population of GPVI molecules,
which facilitate the rapid assembly of GPVI clusters on exposed
collagen following injury.
Figure 8. Tspan9 does not regulate GPVI clustering on collagen. [A] Wild-type (WT) and [B] Tspan9-deficient (KO) mouse platelets were spread on
collagen for 45 minutes, immunostained for GPVI with JAQ3 Fab and anti-rat-Alexa 488, and imaged using confocal microscopy (left panels). Collagen
fibres and platelets were imaged by confocal reflection and GPVI overlaid in magenta (right panels). [C] Wild-type (WT) and [D] Tspan9-deficient (KO)
mouse platelets, labelled for GPVI (JAQ3 and anti-rat-Alexa 647), were imaged using super-resolution dSTORM TIRF (magenta; left panels), which is
overlaid onto a TIRF image of the F-actin labelled with phalloidin-Alexa 488 (green). For quantitative cluster mapping analysis of GPVI localisation, 2 × 2
µm regions of interest were taken inside platelets and along collagen fibres (right panels). Heat maps of the clusters in the regions of interest from [E] wild-
type and [F] Tspan9-deficient platelets are shown (left panels). Binary images of the clusters, following thresholding of the heat map, show clustering of
GPVI along the collagen fibres (right panels). Quantification of GPVI clustering on collagen fibres was made using a custom-made algorithm in
MATLAB, and presented as [G] cluster density and [H] number of clusters that contain at least three molecules per cluster. Data represent means of
medians, and the error bars are standard errors of the mean from four independent experiments. In total, 179 regions were analysed for wild-type mice and
177 regions for Tspan9-deficient mice. Scale bars are 5 μm for panels A and B, 2 μm for panels C and D, and 0.25 μm for panels E and F.
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